Debt-to-equity of Crinetics Pharmaceuticals, Inc. from 31 Mar 2019 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Crinetics Pharmaceuticals, Inc. quarterly Debt-to-equity in % history and change rate from 31 Mar 2019 to 30 Sep 2025.
  • Crinetics Pharmaceuticals, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 10%, a 28% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Crinetics Pharmaceuticals, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 10% -4% -28% 30 Sep 2025
Q2 2025 10% -5% -33% 30 Jun 2025
Q1 2025 10% -5% -33% 31 Mar 2025
Q4 2024 11% -5% -33% 31 Dec 2024
Q3 2024 13% -1% -8.3% 30 Sep 2024
Q2 2024 14% +2% +21% 30 Jun 2024
Q1 2024 15% +5% +44% 31 Mar 2024
Q4 2023 16% +6% +63% 31 Dec 2023
Q3 2023 14% +6% +68% 30 Sep 2023
Q2 2023 12% +4% +43% 30 Jun 2023
Q1 2023 10% +3% +33% 31 Mar 2023
Q4 2022 10% +3% +36% 31 Dec 2022
Q3 2022 9% 0% +2.9% 30 Sep 2022
Q2 2022 8% 0% +2.5% 30 Jun 2022
Q1 2022 8% 0% -1.1% 31 Mar 2022
Q4 2021 7% -1% -15% 31 Dec 2021
Q3 2021 8% -1% -8% 30 Sep 2021
Q2 2021 8% -2% -19% 30 Jun 2021
Q1 2021 8% -3% -28% 31 Mar 2021
Q4 2020 9% -1% -13% 31 Dec 2020
Q3 2020 9% 0% +3.3% 30 Sep 2020
Q2 2020 10% +2% +31% 30 Jun 2020
Q1 2020 11% +2% +20% 31 Mar 2020
Q4 2019 10% 31 Dec 2019
Q3 2019 9% 30 Sep 2019
Q2 2019 8% 30 Jun 2019
Q1 2019 9% 31 Mar 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.